mTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines through Modulating Dendritic Cell Function in the Tumor Microenvironment

• Published in: Cancers Vol. 11; no. 5; p. 617
• Main Authors: Chen, Yu-Li, Lin, Han-Wei, Sun, Nai-Yun, Yie, Jr-Chi, Hung, Hsueh-Chih, Chen, Chi-An, Sun, Wei-Zen, Cheng, Wen-Fang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.05.2019; MDPI
• Subjects: Antigen processing; Antigens; Apoptosis; Bone marrow; Cancer immunotherapy; CD8 antigen; Connective tissue growth factor; Connective tissues; Cytotoxicity; Dendritic cells; Deoxyribonucleic acid; Disease control; DNA; DNA vaccines; Flow cytometry; Glucose; Immunotherapy; Lymphocytes; Lymphocytes T; Maturation; Metabolism; Peptides; Rapamycin; TOR protein; Tumor microenvironment; Vaccines; DNA vaccine; mTOR inhibitor; dendritic cells; tumor microenvironment
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers11050617

The life span of dendritic cells (DCs) can become short following induced activation, which is associated with metabolic transition due to the regulation of mechanistic target of rapamycin (mTOR). The purpose of this study was to investigate the potential of inhibiting mTOR to modulate DC functions for elevating the anti-tumor effects of DNA vaccines. Therefore, the influences of various inhibitors of mTOR (mTORi) on the expressions of DC maturation markers, the abilities of antigen presenting and processing of BMM-derived DCs and the tumor killing effects of E7-specific CD8 T lymphocytes activated by BMM-derived DCs were in vitro examined. The anti-tumor effects of connective tissue growth factor (CTGF)/E7 DNA vaccine and/or mTORi were also in vivo analyzed. In our study, suppressive effects of mTORi on the DC maturation markers expressed on BMMCs could be reversed. The mTORi-treated mature BMM-derived DCs tended to be non-apoptotic. These mTORi-treated BMM-derived DCs could have better antigen presenting and processing abilities. The E7-specific cytotoxic CD8+ T lymphocytes could have more potent tumoricidal activity following activation of mTORi-treated BMM-derived DCs. For tumor-bearing mice, those treated with CTGF/E7 DNA vaccine and mTORi indeed can have higher percentages of mature DCs in the TME, better disease control and longer survivals. Consequently, application of mTORi can be a pharmacological approach for temporally increasing life span, antigen presenting and antigen processing of DCs to strengthen the therapeutic outcome of cancer immunotherapy.